LPL Financial LLC Has $489,000 Stock Holdings in Franklin Genomic Advancements ETF (BATS:HELX)

LPL Financial LLC boosted its holdings in shares of Franklin Genomic Advancements ETF (BATS:HELX) by 19.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 16,965 shares of the company’s stock after purchasing an additional 2,768 shares during the quarter. LPL Financial LLC owned about 5.66% of Franklin Genomic Advancements ETF worth $489,000 at the end of the most recent quarter.

Separately, Halbert Hargrove Global Advisors LLC acquired a new position in Franklin Genomic Advancements ETF during the 4th quarter valued at $52,000.

Franklin Genomic Advancements ETF Price Performance

Shares of Franklin Genomic Advancements ETF stock opened at $27.12 on Friday. The company has a market cap of $10.85 million, a PE ratio of 31.84 and a beta of 1.15. The firm has a fifty day moving average price of $27.51 and a two-hundred day moving average price of $29.40. Franklin Genomic Advancements ETF has a fifty-two week low of $23.74 and a fifty-two week high of $33.98.

About Franklin Genomic Advancements ETF

The Franklin Genomic Advancements ETF (HELX) is an exchange-traded fund that is based on the Solactive Genomics index. The fund is an actively managed portfolio of global equity securities of companies relevant to genomic discovery. HELX was launched on Feb 25, 2020 and is managed by Franklin Templeton.